

84. (New) The method of Claim 83, wherein the animal is a human.

#### REMARKS

Applicants respectfully request entry of the instant Amendment to the specification of the continuation application filed herewith. The Amendment revises the specification at page 1 to add a priority claim and a reference to government rights in the application. The specification includes Table 1 at page 20 which has been revised to refer to SEQ ID NO: 1, in accordance with similar amendments in the parent application. None of these revisions add new matter, and therefore entry of the instant Amendment to the specification is believed proper at this time and is respectfully requested. The computer readable form of the sequence listing in this application is identical with that filed in Application Number 09/378,019, filed August 19, 1999. In accordance with 37 CFR 1.821(e), please use the last-filed computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing was included in a separately filed amendment of the parent application for incorporation into the specification.

Applicants respectfully request entry of the instant Amendment to the claims of the continuation application filed herewith, adding new Claims 16-84 as set forth above. The subject matter of the new claims is fully supported in the instant specification and thus there is no issue of new matter. In particular, new Claims 16-60 are directed to preferred species of compounds, as disclosed in instant Tables 1-3, as well as methods of using those compounds to inhibit tumor growth and/or induce apoptosis of cancer cells, in animals, and particularly in humans. To facilitate efficient prosecution, compounds having similar characteristics have been grouped together in the claims. New Claims 61-84 are directed to methods of using the recited compounds to inhibit tumor growth and/or induce apoptosis of cancer cells, in animals, and particularly in humans. Claims directed to the recited compounds themselves were allowed in the parent case. Therefore, since the subject matter of the new claims is fully supported in the specification, entry of the instant Amendment to the claims is believed proper at this time and is respectfully requested.

Applicants respectfully request examination of the instant application on the merits. The Examiner is respectfully invited to call the undersigned with any questions regarding this application.

Respectfully submitted,

SHERIDAN ROSS, P.C.

Dated: 28 DEC 2001

By: Robert D. Traver  
Robert D. Traver  
Registration No. 47,999  
1560 Broadway, Suite 1200  
Denver, CO 80202-5141  
(303) 863-9700

10035662-122801